Case Report on Penpulimab and Anlotinib for Lung Cancer
Author Information
Author(s): Xie Minghong, Zhao Yunlong, Hou Xiaohua, Li Ning, Niu Sha, Xu Xinju
Primary Institution: First Affiliated Hospital of Henan Polytechnic University, Jiaozuo Second People’s Hospital, Jiaozuo, China
Hypothesis
Can the combination of Penpulimab and Anlotinib effectively treat advanced pulmonary giant cell carcinoma with cerebral metastases?
Conclusion
The combination of Penpulimab and Anlotinib shows promising efficacy in treating advanced pulmonary giant cell carcinoma with cerebral metastases.
Supporting Evidence
- The patient showed significant tumor shrinkage after treatment.
- PD-L1 expression was high, supporting the use of immunotherapy.
- The patient has been stable for 26 months without disease progression.
Takeaway
A 67-year-old man with a rare lung cancer had a significant reduction in his tumors after receiving a new treatment combining two drugs.
Methodology
The patient received Penpulimab and Anlotinib along with cranial radiotherapy, followed by monitoring of tumor size and symptoms.
Limitations
The study is based on a single case report, limiting generalizability.
Participant Demographics
67-year-old Chinese male with a history of hypertension and smoking.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website